LOG IN
Analysis
Featured Analysis
Articles by Category
Current Editions
Data Graphics
Discovery & Translation
Hot Topics
BioCentury Podcasts
Special Reports & Presentations
White Papers
BCIQ Data
BCIQ
Company Profiles
Product Profiles
Target Profiles
Financial Dashboards
Events
All Events
East-West Healthcare Reception
Bio€quity Europe
Grand Rounds — U.S.
Grand Rounds — Europe
China Healthcare Summit
East-West Biopharma Summit 2026
Bio€quity Europe 2026
Podcast: The BioCentury Show
Podcast: BioCentury This Week
Webinars
My Workspace
About BioCentury
Management
Analysts & Research Team
Scientific Advisory Board
Contact
Contact Us
Forgot Password
Request a Subscription
Sponsorship & Branding Inquiry
Media Kit
Request BioCentury's BCIQ Brochure
Customer Resource Center
Career Opportunities
Request a Trial
Company Profiles
Target Profiles
Product Profiles
Latest Articles
Commentaries
Deals
Distillery
Emerging Companies
Finance
Politics, Policy & Law
Product Development
Regulation
Targets & Mechanisms
Tools & Techniques
Company Profiles
Target Profiles
Product Profiles
China Healthcare Summit
Bio€quity Europe
Explore BCIQ profiles by entering a target name.
REQUEST A FREE TRIAL
Pipeline
Deals
Financings
Articles
BioCentury
|
Dec 20, 2022
Deals
Dec. 19 Quick Takes: Sanofi, Innate deepen ties with NK licensing deal
Plus: FDA hold on Entrada’s DMD treatment and updates from Atara, AZ, LianBio-Pfizer, F2G, Protillion, and more
Read More
BioCentury
|
Jun 3, 2022
Deals
June 2 Quick Takes: BMS, Immatics expand partnership to allogeneic T cells
Plus Transition’s $50M A round, Centessa’s killed kidney program and updates from Centessa, Aeglea, Immunic and more
Read More
BioCentury
|
Aug 21, 2021
Targets & Mechanisms
Next-generation multiple sclerosis therapies look beyond B cells
Early-stage approaches aim for more precise immune suppression, remyelination
Read More
BioCentury
|
Dec 21, 2020
Deals
Agios to exit oncology, reward investors via Servier deal as lead anemia program nears submission
Amid a changing cancer landscape, Agios is selling its oncology business for at least $1.8 billion, giving Servier a commercial product and a candidate in Phase III testing. The 12-year-old biotech
Read More
BioCentury
|
Aug 20, 2020
Regulation
Pandemic could give advantage to newly approved MS latecomer ofatumumab
Novartis’ once-monthly anti-CD20 mAb is only auto-injectable MS drug targeting B cells
Read More
BioCentury
|
Aug 13, 2020
Finance
F2G raises $60.8M to get new class of antifungal to market
Venture round could carry ‘breakthrough’ antifungal to 2022-23 launch
Read More
BioCentury
|
Aug 11, 2020
Product Development
Remdesivir heads for FDA review as Gilead continues to build manufacturing pipeline
Plus data from Omeros, PTC and a call to make mAbs accessible
Read More
BioCentury
|
Aug 4, 2020
Product Development
Aug. 3 Quick Takes: CymaBay gains on PBC readout; plus expanded labels for Epidiolex, Spravato, Voyager-AbbVie deal ends, Immunic and more
Read More
BioCentury
|
Jun 20, 2020
Deals
Clinical scorecard for COVID-19: lessons from the first wave of controlled trials
An analysis of 25 controlled trials for COVID-19
Read More
BioCentury
|
May 23, 2020
Translation in Brief
A three-compound dengue treatment; plus reversing antibiotic resistance, AbCellera-Lilly, reducing cholesterol with CRISPR and COVID cash for Sherlock
BioCentury’s roundup of preclinical news
Read More
Items per page:
10
1 - 10 of 137